Skip to main content
SpringerLink
Log in

Therapeutic Use of Radionuclides in Bone and Joint Disease

  • Chapter
  • First Online:
Book cover Orthopedic Nuclear Medicine

  • 1355 Accesses

Abstract

Clinically, bone metastases are manifested by pain and the loss of mechanical stability. Standard treatment options for bone metastases include external beam radiotherapy and analgesics. The use of radionuclides provides an alternative modality for controlling pain. The currently routinely employed agents such as Sr-89, Sm-153, and Re-186 have only mild side effects, and response rates of 70–89% can be achieved. The novel radionuclides, such as Lu-177 and Ra-223, have also been reported to have good response rates and low side effects. It was reported that treatment with alpha-emitter Ra-223 also improves survival. Radionuclide therapy provides an attractive alternative to surgical synovectomy in the management of patients suffering from chronic inflammatory joint disease. It is noninvasive and easily accepted by the patient, and the side effects are related to the leakage of radioactivity from the joint requiring special care and follow-up. Other applications of radionuclide therapy for bone tumors such as osteogenic sarcoma and multiple myeloma are still being investigated. Combination of I-131 MIBG with other modalities improves the therapeutic response in patients with refractory or relapsed neuroblastoma. Novel Lu-177 somatostatin analogues appear to be promising in the treatment of relapsed or primary refractory high-risk neuroblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Foley KM (2004) Treatment of cancer-related pain. J Natl Cancer Inst Monogr 32:103–104

    Article  Google Scholar 

  2. Falk S, Dickenson AH (2014) Pain and nociception: mechanisms of cancer-induced bone pain. J Clin Oncol 32:1647–1654

    Article  CAS  PubMed  Google Scholar 

  3. Kane CM, Hoskin P, Bennett MI (2015) Cancer induced bone pain. BMJ 350:h315

    Article  PubMed  Google Scholar 

  4. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP (2002) Molecular mechanisms of cancer pain. Nat Rev Cancer 2:201–209

    Article  CAS  PubMed  Google Scholar 

  5. Apfel SC (2000) Neurotrophic factors and pain. Clin J Pain 16:S7–S11

    Article  CAS  PubMed  Google Scholar 

  6. Dray A (1995) Inflammatory mediators of pain. Br J Anaesth 75:125–131

    Article  CAS  PubMed  Google Scholar 

  7. Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294:1871–1875

    Article  CAS  PubMed  Google Scholar 

  8. Ueno A, Oh-ishi S (2002) Critical roles for bradykinin and prostanoids in acute inflammatory reactions: a search using experimental animal models. Curr Drug Targets Inflamm Allergy 1:363–376

    Article  CAS  PubMed  Google Scholar 

  9. Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ (1995) Contribution of interleukin-1 beta to the inflammation induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 115:1265–1275

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sorkin LS, Xiao WH, Wagner R, Myers RR (1997) Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 81:255–262

    Article  CAS  PubMed  Google Scholar 

  11. Mantyh WG, Jimenez-Andrade JM, Stake JI, Bloom AP, Kaczmarska MJ (2010) Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. Neuroscience 171:588–598

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Poulson HS, Nielsen OS, Klee M, Rørth M (1989) Palliative irradiation of bone metastases. Cancer Treat Rev 16:41–48

    Article  Google Scholar 

  13. Tong D, Gillick L, Hendrickson FR (1982) Palliation of symptomatic osseous metastases. Cancer 50:893–899

    Article  CAS  PubMed  Google Scholar 

  14. Salazar OM, Rubin P, Hendrickson FR, Komaki R, Poulter C et al (1986) Single dose half-body irradiation for palliations of multiple bone metastases from solid tumors. Final radiation therapy oncology group report. Cancer 58:29–36

    Article  CAS  PubMed  Google Scholar 

  15. Robinson RG, Preston DF, Schiefelbein M, Baxter KG (1995) Strontium-89 therapy for the palliation of pain due to osseous metastases. JAMA 274:420–424

    Article  CAS  PubMed  Google Scholar 

  16. Papatheofanis FJ (1999) Variation in oncologic opinion regarding management of metastatic bone pain with systemic radionuclide therapy. J Nucl Med 40:1420–1423

    CAS  PubMed  Google Scholar 

  17. Quirijnen JP, Han SH, Zonnenberg M et al (1996) Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med 37:1511–1515

    CAS  PubMed  Google Scholar 

  18. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM et al (1998) Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16:1574–1581

    Article  CAS  PubMed  Google Scholar 

  19. Turner PG, O'Sullivan J (2014) Radium-223 dichloride for the treatment of metastatic prostate cancer. Expert Opin Pharmacother 15:2105–2111

    Article  CAS  PubMed  Google Scholar 

  20. Chakravarty R, Chakraborty S, Ram R, Nair KV, Rajeswari A et al (2016) Palliative care of bone pain due to skeletal metastases: exploring newer avenues using neutron activated (45)Ca. Nucl Med Biol 43:140–149

    Article  CAS  PubMed  Google Scholar 

  21. Pauwels EKJ, Stokkel MPM (2001) Radiopharmaceuticals for bone lesions imaging and therapy in clinical practice. Q J Nucl Med 45:18–26

    CAS  PubMed  Google Scholar 

  22. Elgazzar AH, Maxon HR (1993) Radioisotope therapy for cancer related bone pain. Imaging Insights 2:1–6

    Google Scholar 

  23. Giammarile F, Mognetti T, Resche I (2001) Bone pain palliation with strontium-89 in cancer patients with bone metastases. Quart J Nucl Med 45:78–83

    CAS  Google Scholar 

  24. Patel BR, Flowers WM Jr (1997) Systemic radionuclide therapy with strontium chloride Sr 89 for painful skeletal metastases in prostate and breast cancer. South Med J 90:506–508

    Article  CAS  PubMed  Google Scholar 

  25. Papatheofanis FJ (2000) Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain. J Nucl Med 41:1021–1024

    CAS  PubMed  Google Scholar 

  26. Ramamoorthy N, Saraswathy P, Das MK, Mehra KS, Ananthakrishnan M (2002) Production logistics and radionuclide purity aspects of 153Sm for radionuclide therapy. Nucl Med Commun 23:83–89

    Article  CAS  PubMed  Google Scholar 

  27. Cameron PJ, Klemp PF, Martindale AA, Turner JH (1999) Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy. Nucl Med Commun 20:609–615

    Article  CAS  PubMed  Google Scholar 

  28. Maxon HR, Thomas S, Hertzberg VS, Schroder LE, Englaro EE et al (1992) Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin Nucl Med 22:33–40

    Article  PubMed  Google Scholar 

  29. Han SH, De Klerk JM, Zonnenberg BA, Tan S, van Rijk PP (2001) 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases. Quart J Nucl Med 45:84–90

    CAS  Google Scholar 

  30. Kucuk NO, Ibis E, Aras G, Baltaci S, Ozalp G et al (2000) Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases. Ann Nucl Med 14:239–245

    Article  CAS  PubMed  Google Scholar 

  31. Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Cabahug CJ et al (1995) Tin-117m (4+)-DTPA for palliation of pain from osseous metastases: a pilot study. J Nucl Med 36:725–729

    CAS  PubMed  Google Scholar 

  32. Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Straub RF et al (1993) Biodistribution of Sn-117m DTPA for palliative therapy of painful osseous metastases. Radiology 186:279–283

    Article  CAS  PubMed  Google Scholar 

  33. Bishayee A, Rao DV, Srivastava SC, Bouchet LG, Bolch WE et al (2000) Marrow-sparing effects of 117mSn-diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J Nucl Med 41:2043–2050

    CAS  PubMed  Google Scholar 

  34. Blower PJ, Kettle AG, O'Doherty MJ, Coakley AJ, Knapp FF Jr (2000) 99mTc(V)DMSA quantitatively predicts 188Re(V)DMSA distribution in patients with prostate cancer metastatic to bone. Eur J Nucl Med 27:1405–1409

    Article  CAS  Google Scholar 

  35. ter Heine R, Lange R, Breukels OB, Bloemendal HJ, Rummenie RG et al (2014) Bench to bedside development of GMP grade rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases. Int J Pharm 465:317–324

    Article  PubMed  CAS  Google Scholar 

  36. Florimonte L, Dellavedova L, Maffioli LS (2016) Radium-223 dichloride in clinical practice: a review. Eur J Nucl Med Mol Imaging 43:1896–1909

    Article  CAS  PubMed  Google Scholar 

  37. Krishnamurthy GT, Krishnamurthy S (2000) Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium (comment). J Nucl Med 41:688–691

    CAS  PubMed  Google Scholar 

  38. Hoskin PJ, Ford HT, Harmer CL (1989) Hemibody irradiation (HBI) for metastatic bone pain in two histologically distinct groups of patients. Clin Oncol R Coll Radiol 1:67–69

    Article  CAS  PubMed  Google Scholar 

  39. Wessels BW, Meares CF (2000) Physical and chemical properties of radionuclide therapy. Semin Radiat Oncol 10:115–122

    Article  CAS  PubMed  Google Scholar 

  40. Srivastava S, Dadachova E (2001) Recent advances in radionuclide therapy. Semin Nucl Med 31:330–341

    Article  CAS  PubMed  Google Scholar 

  41. Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M et al (2001) A multicenter observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 28:788–798

    Article  CAS  PubMed  Google Scholar 

  42. Guerra Liberal FD, Tavares AA, Tavares JM (2014) Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods. Med Phys 41:114101

    Article  PubMed  CAS  Google Scholar 

  43. Guerra Liberal FD, Tavares AA, Tavares JM (2016) Palliative treatment of metastatic bone pain with radiopharmaceuticals: a perspective beyond strontium-89 and samarium-153. Appl Radiat Isot 110:87–99

    Article  CAS  PubMed  Google Scholar 

  44. Silberstein EB, Elgazzar AH, Kapilivsky A (1992) Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases. Semin Nucl Med 17:17–27

    Article  Google Scholar 

  45. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ et al (1994) A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31:33–40

    Article  CAS  PubMed  Google Scholar 

  46. Lange R, Overbeek F, de Klerk JM, Pasker-de Jong PC, van den Berk AM et al (2016) Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study. Nuklearmedizin 55:188–195

    Article  PubMed  Google Scholar 

  47. Windsor PM (2001) Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre’s 10-year experience. Clin Oncol (R Coll Radiol) 13:219–227

    CAS  Google Scholar 

  48. Dickie GJ, Macfarlane D (1999) Strontium and samarium therapy for bone metastases from prostate carcinoma. Austr Radiol 43:476–479

    Article  CAS  Google Scholar 

  49. Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S et al (2001) Metastatic bone pain palliation with 89-Sr and 186-re-HEDP in breast cancer patients. Breast Cancer Res Treat 66:101–109

    Article  CAS  PubMed  Google Scholar 

  50. Ashayeri E, Omogbehin A, Sridhar R, Shakar RA (2002) Stronium-89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience. J Natl Med Assoc 94:706–711

    PubMed  PubMed Central  Google Scholar 

  51. Kvinnsland Y, Skretting A, Bruland OS (2001) Radionuclide therapy with bone-seeking compounds: Monte Carlo calculations of dose-volume histograms for bone marrow in trabecular bone. Phys Med Biol 46:1149–1161

    Article  CAS  PubMed  Google Scholar 

  52. Correa-González L, Arteaga de Murphy C, Pichardo-Romero P, Pedraza-López M, Moreno-García C et al (2014) (153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies. Arch Med Res 45:301–308

    Article  PubMed  CAS  Google Scholar 

  53. Li S, Liu J, Zhang H, Tian M, Wang J et al (2001) Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med 11:919–922

    Article  Google Scholar 

  54. Jong JM, Oprea-Lager DE, Hooft L, de Klerk JM, Bloemendal HJ et al (2016) Radiopharmaceuticals for palliation of bone pain in patients with castration-resistant prostate cancer metastatic to bone: a systematic review. Eur Urol 70:416–426

    Article  PubMed  Google Scholar 

  55. Agarwal KK, Singla S, Arora G, Bal C (2015) (177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur J Nucl Med Mol Imaging 42:79–88

    Article  CAS  PubMed  Google Scholar 

  56. Thapa P, Nikam D, Das T, Sonawane G, Agarwal JP et al (2015) Clinical efficacy and safety comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equi dose basis in patients with painful skeletal metastases. J Nucl Med 56:1513–1519

    Article  CAS  PubMed  Google Scholar 

  57. Alavi M, Omidvari S, Mehdizadeh A, Jalilian AR, Bahrami-Samani A (2015) Metastatic bone pain palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic acid. World J Nucl Med 14:109–115

    Article  PubMed  PubMed Central  Google Scholar 

  58. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R et al (2013) Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer 11:20–26

    Article  PubMed  Google Scholar 

  59. Coleman R (2016) Treatment of metastatic bone disease and the emerging role of radium-223. Semin Nucl Med 46:99–104

    Article  PubMed  Google Scholar 

  60. ClinicalTrials.gov. National Institutes of Health. Available at: https://clinicaltrials.gov/

  61. Brady D, Parker C, O’Sullivan JM (2013) Bone-targeting radiopharmaceuticals including radium-223. Cancer J 19:71–78

    Article  CAS  PubMed  Google Scholar 

  62. Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF et al (2011) Palliation and survival after repeated (188) re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med 52:1721–1726

    Article  CAS  PubMed  Google Scholar 

  63. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM et al (2013) ALSYMPCA investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223

    Article  CAS  PubMed  Google Scholar 

  64. Palmedo H, Grunwald F, Wagner U, Kohler S, Krebs D et al (1998) Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP. Clin Nucl Med 23:501–504

    Article  CAS  PubMed  Google Scholar 

  65. Autio KA, Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF et al (2013) Repetitively dosed docetaxel and 153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer 119:3186–3194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Suttmann H, Grgic A, Lehmann J, Zwergel U, Kamradt J et al (2008) Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience. Cancer Biother Radiopharm 23:609–618

    Article  CAS  PubMed  Google Scholar 

  67. Hoskin P, Sartor O, ÓSullivan JM, Johannessen DC, Helle SI et al (2014) Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomized, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 15:1397–1406

    Article  CAS  PubMed  Google Scholar 

  68. Nilsson S (2016) Radionuclide therapies in prostate cancer: integrating radium-223in the treatment of patients with metastatic castration-resistant prostate cancer. Curr Oncol Rep 18:14

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Zafeirakis A, Zissimopoulos A, Baziotis N, Limouris GS (2009) Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. Cancer Biother Radiopharm 24:543–550

    Article  CAS  PubMed  Google Scholar 

  70. Sideras PA, Stavraka A, Gouliamos A, Limouris GS (2013) Radionuclide therapy of painful bone metastases—a comparative study between consecutive radionuclide infusions, combination with chemotherapy, and radionuclide infusions alone: an in vivo comparison of their effectiveness. Am J Hosp Palliat Care 30:745–751

    Article  PubMed  Google Scholar 

  71. Moro L, Fantinato D, Aprile C, Preti P, Robustelli della Cuna G (2001) 153Sm-EDTMP radionuclide treatment of bony metastatic disease: a radiation protection evaluation. G Ital Med Lav Ed Ergon 23:435–437

    CAS  Google Scholar 

  72. Zanzonico PB, Siegel JA, St Germain J (2000) A generalized algorithm for determining the time of release and the duration of post-release radiation precautions following radionuclide therapy. Health Phys 78:648–659

    Article  CAS  PubMed  Google Scholar 

  73. Siegel ME, Siegel HJ, Luck JV Jr (1997) Radiosynovectomy’s clinical applications and cost effectiveness: a review. Semin Nucl Med 28:364–371

    Article  Google Scholar 

  74. Heim M, Goshen E, Amit Y, Martinowitz U (2001) Synoviorthesis with radioactive yttrium in haemophilia: Israel experience. Haemophilia 7(Suppl 2):36–39

    Article  PubMed  Google Scholar 

  75. Rodriguez-Merchan EC, Jimenez-Yuste V, Villar A, Quintana M, Lopez-Cabarcos C et al (2001) Yttrium-90 synoviorthesis for chronic haemophilic synovitis: Madrid experience. Haemophilia 7(Suppl 2):34–35

    Article  PubMed  Google Scholar 

  76. Gencoglu EA, Aras G, Kucuk O, Atay G, Tutak I et al (2002) Utility of Tc-99m human polyclonal immunoglobulin G scintigraphy for assessing the efficacy of yttrium-90 silicate therapy in rheumatoid knee synovitis. Clin Nucl Med 27:395–400

    Article  PubMed  Google Scholar 

  77. Onetti CM, Guyierrez F, Hiba E et al (1982) Synoviorthesis with P-32 colloid chromic phosphate in rheumatoid arthritis and hemophilia, clinical, histopathological and arthographic changes. J Rheumatol 9:229–238

    CAS  PubMed  Google Scholar 

  78. Rivard GE, Givard M, Belanger R, Jutras M, Guay JP et al (1994) Synoviortheses with colloidal P-32 chromic phosphate for the treatment of hemophilic arthropathy. J Bone Joint Surg Am 76:482–487

    Article  CAS  PubMed  Google Scholar 

  79. Jeong JM, Lee YJ, Kim YJ, Chang YS, Lee DS et al (2000) Preparation of rhenium-188-tin colloid as a radiation synovectomy agent and comparison with rhenium-188-sulfur colloid. Appl Radiat Isot 52:851–855

    Article  CAS  PubMed  Google Scholar 

  80. Ofluoglu S, Schwameis E, Zehetagruber I, Havlic E, Wanivenhaus A et al (2002) Radiation synovectomy with Ho-166-ferric hydroxide: a first experience. J Nucl Med 43:1489–1494

    CAS  PubMed  Google Scholar 

  81. Clunie G, Lui D, Cullum I, Edwards JC, Ell PJ (1995) Samarium-153-particulate hydroxyapatite radiation synovectomy: biodistribution data for chronic knee synovitis. J Nucl Med 36:51–57

    CAS  PubMed  Google Scholar 

  82. Torres M, Ayra E, Albuerne O, Montano DMA (2009) Absorbed dose profiles for (32)P, (90)Y, (188)Re, (177)Lu, (153)Sm and (169)Er: radionuclides used in radiosynoviortheses treatment. Rev Esp Med Nucl 28:188–192

    Article  CAS  PubMed  Google Scholar 

  83. Fischer M, Modder G (2002) Radionuclide therapy of inflammatory joint disease. Nucl Med Commun 23:829–831

    Article  PubMed  Google Scholar 

  84. Fernandez-Palazzi F, Rivas S, Ciberia JL, Dib O, Viso R (1996) Radioactive synoviorthesis in hemophiliac hemarthrosis: materials, techniques and dangers. Clin Orthop 328:14–18

    Article  Google Scholar 

  85. Barber TW, Yap KS, Kalff V (2012) PET/CT imaging of 90Y radiation synovectomy. Eur J Nucl Med Mol Imaging 39:917–918

    Article  PubMed  Google Scholar 

  86. Hauss F (1992) Radiosynoviortheses in der Orthopadie. Aktuel Rheumatol 17:64–66

    Article  Google Scholar 

  87. Asavatanabodee P, Sholter D, Davis P (1997) Yttrium-90 radiochemical synovectomy in chronic knee synovitis: a one year retrospective review of 133 treatment interventions. J Rheumatol 24:639–642

    CAS  PubMed  Google Scholar 

  88. Deutsch E, Brodack JW, Deutsch KF (1993) Radiation synovectomy revisited. Eur J Nucl Med 20:1113–1127

    Article  CAS  PubMed  Google Scholar 

  89. Kresnik E, Mikososch P, Gallowitsch HJ, Jesenko R, Just H et al (2002) Clinical outcome of radiosynoviorthesis: a meta-analysis including 2190 treated joints. Nucl Med Commun 23:683–688

    Article  CAS  PubMed  Google Scholar 

  90. Rodriguez-Merchan EC, De la Corte-Rodriguez H, Jimenez-Yuste V (2014) Radiosynovectomy in haemophilia: long-term results of 500 procedures performed in a 38-year period. Thromb Res 134:985–990

    Article  CAS  PubMed  Google Scholar 

  91. Calegaro JU, Machado J, Furtado RG, de Almeida JS, de Vasconcelos AV et al (2014) The use of 185 MBq and 740 MBq of 153-samarium hydroxyapatite for knee synovectomy in haemophilia. Haemophilia 20:421–425

    Article  CAS  PubMed  Google Scholar 

  92. Erkon EHW (1991) Radiocolloids in the management of hemophilic arthropathy in children and adolescents. Clin Orthop 264:129–134

    Google Scholar 

  93. Siegel HJ, Luck JV Jr, Siegel ME, Quines C, Anderson E (1994) Hemarthrosis and synovitis associated with hemophilia: clinical use of P-32 chromic phosphate synoviorthesis for treatment. Radiology 190:297–261

    Article  Google Scholar 

  94. Chew EM, Tien SL, Sundram FX et al (2003) Radionuclide synovectomy and chronic haemophilic synovitis in Asians: a retrospective study. Haemophilia 9:632–637

    Article  CAS  PubMed  Google Scholar 

  95. Athanasou NA, Quinn J, Heryet A, Puddle B, Woods CG et al (1988) The immunohistology of synovial lining cells in normal and inflamed synovium. J Pathol 155:133–142

    Article  CAS  PubMed  Google Scholar 

  96. Henderson B, Edwards JCW (1987) The synovial lining, in health and disease. Chapman and Hall, London

    Google Scholar 

  97. Gobel D, Gratz S, von Rothkirch T, Becker W (1997) Chronische Polyarthritis und Radiosynoviorthese: eine prospektive, kontrollierte Studie der Injektionstherapie mit Erbium-169 und Rhenium-186. Z Rheumatol 56:207–213

    Article  CAS  PubMed  Google Scholar 

  98. Gobel D, Gratz S, von Rothkirch T, Becker W, Willert HG (1997) Radiosynoviorthesis with rhenium-186 in rheumatoid arthritis: a prospective study of three treatment regiment. Rheumatol Int 17:105–108

    Article  CAS  PubMed  Google Scholar 

  99. Ahlberg A, Mikulowski P, Odelberg-Johnson O (1969) Intra-articular injection of radioactive gold in treatment of chronic synovial effusion in the knee. Acta Rheum Scand 15:81–89

    Article  CAS  PubMed  Google Scholar 

  100. Ansell BM, Crook A, Mallard JR et al (1966) Treatment of persistent knee effusions with intra-articular radioactive gold. In: Studies of rheumatic disease. Proceedings of 3rd Canadian conference on research in rheumatic disease. University of Toronto Press, Toronto

    Google Scholar 

  101. Ansell BM, Crook A, Mallard JR, Bywaters EG (1963) Evaluation of intra-articular colloidal gold Au-198 in the treatment of persistent knee effusion. Ann Rheum Dis 22:435–439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Jalava S (1973) Irradiation synovectomy: clinical study of 67 knee effusions in intra-articularly irradiated with Y-90 resin. Curr Ther Res 15:395–401

    CAS  PubMed  Google Scholar 

  103. Menkes CJ, Tubiana R, Galmiche B, Delbarre F (1973) Intra-articular injection of radio-isotopic beta emitters. Orthop Clin North Am 4:1113–1125

    CAS  PubMed  Google Scholar 

  104. Gumpel JM, Williams ED, Glass HI (1973) Use of yttrium-90 in persistent synovitis of the knee. I. Retention in the knee and spread in the body after injection. Ann Rheum 32:223–227

    Article  CAS  Google Scholar 

  105. Grove F (1995) Radio synovectomy: clinical review. Presented at the world congress of nuclear medicine and biology, Sydney, Australia

    Google Scholar 

  106. Kraft O, Kašparek R (2011) Effectiveness of radiosynoviorthesis in the treatment of chronic synovitis of small and middle-sized joints affected by rheumatoid arthritis. Hell J Nucl Med 14:251–254

    PubMed  Google Scholar 

  107. Clunie G, Lui D, Cullum I, Ell PJ, Edwards JC (1996) Clinical outcome after one year following samarium-153 particulate hydroxyapatite radiation synovectomy. Scand J Rheumatol 25:360–366

    Article  CAS  PubMed  Google Scholar 

  108. Chakraborty S, Das T, Banerjee S, Sarma HD, Venkatesh M (2006) Preparation and preliminary biological evaluation of 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints. Nucl Med Commun 27:661–668

    Article  PubMed  Google Scholar 

  109. Chakraborty S, Vimalnath KV, Rajeswari A, Shinto A, Sarma HD et al (2014) Preparation, evaluation, and first clinical use of 177Lu-labeled hydroxyapatite (HA) particles in the treatment of rheumatoid arthritis: utility of cold kits for convenient dose formulation at hospital radiopharmacy. J Labelled Comp Radiopharm 57:453–462

    Article  CAS  PubMed  Google Scholar 

  110. Dos Santos MF, Furtado RN, Konai MS, Castiglioni ML, Marchetti RR et al (2011) Effectiveness of radiation synovectomy with yttrium-90 and samarium-153 particulate hydroxyapatite in rheumatoid arthritis patients with knee synovitis: a controlled, randomized, double-blinded trial. Clin Rheumatol 30:77–85

    Article  PubMed  Google Scholar 

  111. Franssen MJAM, Boerboom ANT, Kerthaus RP et al (1989) Treatment of pig mounted vilonodular synovitis of the knee with Y-90 silicate. Ann Rheum Dis 48:1007–1013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Alexieva T, Kunnev K (1990) The treatment of gonathritis with Y-90. Vutr Voles 29:59–61

    Google Scholar 

  113. Fischer M (1999) Society of Nuclear Medicine, Proceedings, pp 353–355

    Google Scholar 

  114. Panholzer PJ et al (2000) Effiziente Lokalbehandlung der Psoriasis-Arthritis mit der Radiosynoviorthese (RSO). DGN 29:13–14

    Google Scholar 

  115. De la Chapelle A, Oka M, Rekonen A, Ruotsi A (1972) Chromosome damage after intra articular injection of radioactive yttrium. Ann Rheum Dis 31:508–512

    Article  PubMed  PubMed Central  Google Scholar 

  116. Gumpel JM (1978) Radiosynoviorthesis. Clin Rheum Dis 41:311–326

    Google Scholar 

  117. Noble J, Jones AG, Davies MA, Sledge CB, Kramer RI et al (1983) Leakage of radioactive particle systems from a synovial joint studied with a gamma camera. J Bone Joint Surg 65-A:381–389

    Article  Google Scholar 

  118. Siegel ME, Luck JV Jr, Siegel HJ (1997) Radiosynoviorthesis for chronic hemophilic hemarthrosis and synovitis: efficacy and cost analysis. J Nucl Med 38:120–121

    Google Scholar 

  119. Winston MA, Bluestone R, Cracchiolo A III, Blahd WH (1973) Radioisotope synovectomy with P-32 chromic phosphate-kinetic studies. J Nucl Med 14:886–889

    CAS  PubMed  Google Scholar 

  120. Klett R, Puille M, Matter HP, Steiner D, Sturz H, Bauer R et al (1999) Aktivitatsa tansport und Strahlenexposition durch die Radiosynoviorthese des Kniegelenks: Einfluss unterschiedlicher Therapiemodalitaten. Z Rheumatol 58:207–212

    Article  CAS  PubMed  Google Scholar 

  121. Bruland OS, Skretting A, Solheim OP, Aas M (1996) Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. Acta Oncol 35:381–384

    Article  CAS  PubMed  Google Scholar 

  122. Franzius C, Bielack S, Sciuk J, Vollet B, Jurgens H, Schober O (1999) High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma. Nucl Med 38:337–340

    CAS  Google Scholar 

  123. Aas M, Moe L, Gamlem H, Skretting A, Ottesen N, Bruland OS (1999) Internal radionuclide therapy of primary osteosarcoma in dogs, using 153Sm-ethylene-diamino-tetramethylene-phosphonate (EDTMP). Clin Cancer Res 5(Suppl 10):3148s–3152s

    CAS  PubMed  Google Scholar 

  124. Anderson PM, Subbiah V, Rohren E (2014) Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. Adv Exp Med Biol 804:291–304

    Article  CAS  PubMed  Google Scholar 

  125. Geldof AA, van den Tillaar PL, Newling DW, Teule GJ (1997) Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model. Urology 49:795–801

    Article  CAS  PubMed  Google Scholar 

  126. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M et al (2016) German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med Oct 20. pii: jnumed.116.183194

    Google Scholar 

  127. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S et al (2016) 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med 57:1006–1013

    Article  PubMed  Google Scholar 

  128. Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M et al (2016) Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med 41:522–528

    Article  PubMed  Google Scholar 

  129. Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M et al (2016) PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med 57:1170–1176

    Article  PubMed  Google Scholar 

  130. Rajendran JG, Eary JF, Bensinger W, Durack LD, Vernon C et al (2002) High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. J Nucl Med 43:1383–1390

    CAS  PubMed  Google Scholar 

  131. Alexanan R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330:484–489

    Article  Google Scholar 

  132. Barlogie B, Alexanian R, Dick KA et al (1987) High dose chemotherapy and autologous bone marrow transplantation for resistant myeloma. Blood 70:869–872

    CAS  PubMed  Google Scholar 

  133. Gouard S, Pallardy A, Gaschet J, Faivre-Chauvet A, Bruchertseifer F et al (2014) Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy. Nucl Med Biol 41(Suppl):e30–e35

    Article  CAS  PubMed  Google Scholar 

  134. Chérel M, Gouard S, Gaschet J, Saï-Maurel C, Bruchertseifer F et al (2013) 213Biradioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med 54:1597–1604

    Article  PubMed  CAS  Google Scholar 

  135. Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A et al (2016) First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med 57:248–251

    Article  CAS  PubMed  Google Scholar 

  136. Hoefnagel CA (1988) Radionuclide cancer therapy. Ann Nucl Med 12:61–70

    Article  Google Scholar 

  137. Matthay KK, Yanik G, Messina J, Quach A, Huberty J et al (2007) Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25:1054–1060

    Article  CAS  PubMed  Google Scholar 

  138. Klingebiel T, Bader P, Bares R, Beck J, Hero B et al (1998) Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 34:1398–1402

    Article  CAS  PubMed  Google Scholar 

  139. Yanik G, Levine JE, Matthay KK, Sisson JC, Shulkin BL et al (2002) Pilot study of iodine-131-metaiosobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 20:2142–2149

    Article  CAS  PubMed  Google Scholar 

  140. Matthay K, Tan JC, Villablanca JG, Yanik GA, Veatch J et al (2006) Phase1 dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. J Clin Oncol l24:500–506

    Article  CAS  Google Scholar 

  141. Yanik GA, Villablanca J, Maris JM, Weiss B, Groshen S et al (2015) 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant 21:673–681

    Article  CAS  PubMed  Google Scholar 

  142. Roa WH, Yaremko B, McEwan A, Amanie J, Yee D et al (2013) Dosimetry study of [I-131] and [I-125]-meta-iodobenz guanidine in a simulating model for neuroblastoma metastasis. Technol Cancer Res Treat 12:79–90

    Article  CAS  PubMed  Google Scholar 

  143. Gains JE, Bomanji JB, Fersht NL, Sullivan T, D’Souza D et al (2011) 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med 52:1041–1047

    Article  PubMed  Google Scholar 

  144. Kong G, Hofman MS, Murray WK, Wilson S, Wood P et al (2016) Initial experience with gallium-68 DOTA-Octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. J Pediatr Hematol Oncol 38:87–96

    Article  CAS  PubMed  Google Scholar 

  145. Parks NJ, Kawakami TG, Avila MJ, White R, Cain GR et al (1993) Bone marrow transplantation in dogs after radio-ablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP). Blood 82:318–325

    CAS  PubMed  Google Scholar 

  146. Ferrant A, Cogneau M, Leners N, Jamar F, Martiat P et al (1993) 52Fe for additional marrow ablation before bone marrow transplantation. Blood 81:3435–3439

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Kuwait University, Safat, Kuwait

    Abdelhamid H. Elgazzar

Authors
  1. Abdelhamid H. Elgazzar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Elgazzar, A.H. (2017). Therapeutic Use of Radionuclides in Bone and Joint Disease. In: Orthopedic Nuclear Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-56167-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56167-7_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56165-3

  • Online ISBN: 978-3-319-56167-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation